MUC16 and ovarian serous adenocarcinoma: indicated that in high-grade serous ovarian cancer patients’ serum samples, an increase in MUC16 was positively correlated with the rise of immunosuppressive factors like IL-10 and negatively correlated with overall survival rates, suggesting MUC16 as an adverse prognostic marker (90).